{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cognitive+Control&page=2",
    "query": {
      "condition": "Cognitive Control",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cognitive+Control&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T09:15:57.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02519777",
      "title": "Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Placebo for maraviroc (MVC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Maraviroc (MVC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2016-04-21",
      "completion_date": "2021-01-05",
      "has_results": true,
      "last_update_posted_date": "2022-04-22",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • San Diego, California • Torrance, California + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02519777"
    },
    {
      "nct_id": "NCT06570954",
      "title": "Retraining and Control Therapy (ReACT)- Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Convulsion, Non-Epileptic"
      ],
      "interventions": [
        {
          "name": "ReACT",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-04-10",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06570954"
    },
    {
      "nct_id": "NCT01421056",
      "title": "Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CHF 5074 1x",
          "type": "DRUG"
        },
        {
          "name": "CHF 5074 2x",
          "type": "DRUG"
        },
        {
          "name": "CHF 5074 3x",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 74,
      "start_date": "2011-07",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2014-02-06",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 4,
      "location_summary": "Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more",
      "locations": [
        {
          "city": "Eatontown",
          "state": "New Jersey"
        },
        {
          "city": "Monroe Twp",
          "state": "New Jersey"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421056"
    },
    {
      "nct_id": "NCT02378896",
      "title": "Personalized Computerized Inhibitory Control Training for OCD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obsessive-Compulsive Disorder"
      ],
      "interventions": [
        {
          "name": "Personalized Computer Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 11,
      "start_date": "2015-02",
      "completion_date": "2018-01",
      "has_results": false,
      "last_update_posted_date": "2018-01-29",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02378896"
    },
    {
      "nct_id": "NCT02738450",
      "title": "Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Down Syndrome"
      ],
      "interventions": [
        {
          "name": "ACI-24 low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24 high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AC Immune SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "25 Years to 45 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-03",
      "completion_date": "2020-06",
      "has_results": true,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02738450"
    },
    {
      "nct_id": "NCT02287038",
      "title": "Atomoxetine in Veterans With Comorbid ADHD/PTSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder",
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Atomoxetine 80 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "20 Years to 60 Years"
      },
      "enrollment_count": 44,
      "start_date": "2014-10-15",
      "completion_date": "2017-04-14",
      "has_results": true,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287038"
    },
    {
      "nct_id": "NCT06418997",
      "title": "Cognitive Behavioral Immersion: A Randomized Control Trial of Peer-Based Coaching in the Metaverse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression, Anxiety"
      ],
      "interventions": [
        {
          "name": "CBI",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2024-02-26",
      "completion_date": "2025-09-24",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06418997"
    },
    {
      "nct_id": "NCT05994391",
      "title": "A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LasoperinTM on Cognitive Function in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cognitive Impairment",
        "Cognitive Decline",
        "Cognition Disorders in Old Age",
        "Well-Being, Psychological",
        "Inflammation",
        "Cognitive Fun"
      ],
      "interventions": [
        {
          "name": "LasoperinTM",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placeo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Lindenwood University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "30 Years to 60 Years"
      },
      "enrollment_count": 100,
      "start_date": "2022-06-03",
      "completion_date": "2022-10-18",
      "has_results": false,
      "last_update_posted_date": "2023-08-16",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05994391"
    },
    {
      "nct_id": "NCT03112759",
      "title": "Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Pancreatitis"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-09-09",
      "completion_date": "2020-03-26",
      "has_results": false,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03112759"
    },
    {
      "nct_id": "NCT04078178",
      "title": "Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cognition Disorders in Old Age",
        "Mild Cognitive Impairment",
        "Cognitive Decline"
      ],
      "interventions": [
        {
          "name": "Niagen",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Comparator",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Steven E Arnold, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2020-10-30",
      "completion_date": "2022-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-11-29",
      "last_synced_at": "2026-06-26T09:15:57.818Z",
      "location_count": 1,
      "location_summary": "Charlestown, Massachusetts",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04078178"
    }
  ]
}